Celltrion fined in South Korea over cancelled Covid-19 test kit orders
( October 29, 2026, 04:35 GMT | Official Statement) -- MLex Summary: South Korean biopharmaceutical company Celltrion has been fined 630 million won ($472,000) for unfair subcontracting practices involving the production of Covid-19 rapid diagnostic test kits, including the unilateral cancellation of orders for roughly 37.2 million kits. The Korea Fair Trade Commission said Thursday it found that Celltrion canceled the manufacturing orders in December 2022 despite the subcontractor bearing no responsibility for the termination. The company also failed to issue required written agreements when changing product specifications and, in a separate instance, provided contractual documents only after the subcontractor had begun production. The regulator imposed a corrective order to prevent recurrence, along with fines of 590 million won for the improper cancellations and 40 million won for the documentation violations.Statement is attached (in Korean)....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.